Study of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Participants With Early/Metastatic Breast Cancer in Saudi Arabia
This is a retrospective, multicenter study, consisting of chart review of Saudi Arabian participants diagnosed with breast cancer between 2007 and 2013 and with available human epidermal growth factor receptor 2 (HER2) testing. Data on survival will be collected through 2015.
Breast Cancer
Percentage of Participants With Positive HER2 Test Result, From January 2007 to December 2013 (Up to 7 years; assessed retrospectively)
Percentage of Participants With Estrogen Receptor/Progesterone Receptor Positive Breast Cancer, From January 2007 to December 2013 (Up to 7 years; assessed retrospectively)|Percentage of Participants by Type of First-line and Subsequent Treatment Regimens Used, From January 2007 to December 2013 (Up to 7 years; assessed retrospectively)|Kaplan-Meier Estimate of Overall Survival (OS), From January 2007 to December 2015 (Up to 9 years; assessed retrospectively)|Kaplan-Meier Estimates of Progression-free Survival (PFS) as Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST), From January 2007 to December 2013 (Up to 7 years; assessed retrospectively)|Percentage of Participants With Complete Response as Assessed Using RECIST, From January 2007 to December 2013 (Up to 7 years; assessed retrospectively)|Percentage of Participants With Partial Response as Assessed Using RECIST, From January 2007 to December 2013 (Up to 7 years; assessed retrospectively)|Percentage of Participants With Progressive Disease as Assessed Using RECIST, From January 2007 to December 2013 (Up to 7 years; assessed retrospectively)|Percentage of Participants with Stable Disease as Assessed Using RECIST, From January 2007 to December 2013 (Up to 7 years; assessed retrospectively)|Percentage of Participants With Adverse Events, From January 2007 to December 2013 (Up to 7 years; assessed retrospectively)
This is a retrospective, multicenter study, consisting of chart review of Saudi Arabian participants diagnosed with breast cancer between 2007 and 2013 and with available human epidermal growth factor receptor 2 (HER2) testing. Data on survival will be collected through 2015.